ACTELION EXT · AC-058B202
Public neurological clinical research study information. Check the current recruitment status in the live Wix study record.
A multicenter, randomized, double-blind, parallel-group extension of AC-058B201 evaluating the long-term safety, tolerability and efficacy of oral ACT-128800, an S1P1 receptor agonist, at 10, 20 and 40 mg/day in relapsing-remitting multiple sclerosis. EudraCT: 2009-011470-15.
Sponsor: JANSSEN ACTELION
Phase: II
Area: Neuroimmunology